Amotiv Limited (AOV) - Total Liabilities

Latest as of December 2025: CA$279.03 Million CAD ≈ $201.84 Million USD

Based on the latest financial reports, Amotiv Limited (AOV) has total liabilities worth CA$279.03 Million CAD (≈ $201.84 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Amotiv Limited - Total Liabilities Trend (2014–2025)

This chart illustrates how Amotiv Limited's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Amotiv Limited to evaluate short-term liquidity relative to the company's equity base.

Amotiv Limited Competitors by Total Liabilities

The table below lists competitors of Amotiv Limited ranked by their total liabilities.

Company Country Total Liabilities
Benakat Petroleum Energy
JK:BIPI
Indonesia Rp1.05 Billion
Wesure Global Tech Ltd
TA:WESR
Israel ILA18.79 Billion
Shanghai National Center of Testing and Inspection for Electric Cable and Wire Co. Ltd.
SHE:301289
China CN¥265.46 Million
Gan Yuan Foods Co Ltd
SHE:002991
China CN¥384.61 Million
Sunny Loan Top Co Ltd
SHG:600830
China CN¥3.98 Billion
Shenzhen Properties & Resources Development Group Ltd
SHE:000011
China CN¥11.86 Billion
Shandong Binzhou Bohai Piston Co Ltd
SHG:600960
China CN¥2.71 Billion
Sparebanken Møre
OL:MORG
Norway Nkr100.04 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Amotiv Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AOV company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.39 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.03 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Amotiv Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Amotiv Limited (2014–2025)

The table below shows the annual total liabilities of Amotiv Limited from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 CA$279.03 Million
≈ $201.84 Million
+65.41%
2024-12-31 CA$168.69 Million
≈ $122.03 Million
-15.07%
2023-12-31 CA$198.62 Million
≈ $143.68 Million
-13.26%
2022-12-31 CA$228.98 Million
≈ $165.64 Million
+52.78%
2021-12-31 CA$149.87 Million
≈ $108.42 Million
-2.32%
2020-12-31 CA$153.44 Million
≈ $110.99 Million
-60.68%
2019-12-31 CA$390.20 Million
≈ $282.26 Million
+1689.89%
2018-12-31 CA$21.80 Million
≈ $15.77 Million
+47.55%
2017-12-31 CA$14.78 Million
≈ $10.69 Million
+33.69%
2016-12-31 CA$11.05 Million
≈ $7.99 Million
+59.57%
2015-12-31 CA$6.93 Million
≈ $5.01 Million
-9.14%
2014-12-31 CA$7.62 Million
≈ $5.51 Million
--

About Amotiv Limited

TO:AOV Canada Drug Manufacturers - Specialty & Generic
Market Cap
$681.27 Million
CA$941.78 Million CAD
Market Cap Rank
#11706 Global
#349 in Canada
Share Price
CA$9.29
Change (1 day)
-2.00%
52-Week Range
CA$5.75 - CA$9.48
All Time High
CA$10.90
About

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more